演題詳細

一般口演 / Oral Session

一般口演 101 (Oral Session 101) :悪性リンパ腫:PET/CT・合併症・予後因子

print

日程
2013年10月13日(日)
時間
16:00 - 17:00
会場
第8会場 / Room No.8 (ロイトン札幌 2F ハイネス)
座長・司会
伊豆津 宏二 (Koji Izutsu):1
1:虎の門病院 血液内科
 
前へ戻る

Interim FDG PET-CT in diffuse large B-cell lymphoma

演題番号 : OS-3-151

岡本 裕介 (Yusuke Okamoto):1、塚本 拓 (Taku Tsukamoto):1、山崎 尚也 (Naoya Yamasaki):1、杉浦 弘幸 (Hiroyuki Sugiura):1、松井 宏行 (Hiroyuki Matsui):1、上田 智朗 (Tomoaki Ueda):1、岡田 和也 (Kazuya Okada):1、大西 達人 (Tatsuhito Onishi):1、國富 あかね (Akane Kunitomi):1、石守 崇好 (Takayoshi Ishimori):2、上田 恭典 (Yasunori Ueda):1

1:Department of Haematology/Oncology, Kurashiki Central Hospital、2:Department of Radiology, Kurashiki Central Hospital

 

Backgroud: Role of interim-PET (I-PET) in diffuse large B-cell lymphoma (DLBCL) is controversial. Methods:To determine the predictive value of I-PET on event-free survival (EFS) for patients with DLBCL, we retrospectively analyzed 100 DLBCL patients treated with 6-8 courses R-CHOP in our hospital between February 2007 and February 2012 inclusive. FDG-PET/CT was performed at diagnosis, after 2 to 4 courses, and at the end of therapy (final PET).Results:The results from visual analysis for I-PET were 64% negative and 36% positive, and for final-PET (F-PET), 89% negative and 11% positive, respectively. With a median follow-up of 36.1 months, the 2-year overall survival (OS) and EFS were 81% and 71%, respectively. The 2-year OS and EFS for I-PET negative versus positive were a 2-year OS of 78% versus 75% (P value 0.394). 2 year EFS for the former was 78% versus 77% (P value 0.742) for the latter. Survival curves were estimated with Kaplan Meier analysis and compared using the log-rank test.Discussion:Positive I-PET is not predictive of a worse outcome in DLBCL. On the other hand, an optimal cutoff value of 65.3% SUVmax reduction from baseline to midtherapy obtained from ROC analysis is a predictor of EFS. From analysis of 83 patients in our study, the 2-year EFS was 83% for a SUVmax reduction >65.3% compared with 55% for a reduction <65.3% (P value 0.013).Conclusions:In our data, I-PET is unable to predict a worse outcome in DLBCL, but SUV max reduction criteria may improve prognostic value of I-PET, and larger prospective studies are necessary.

前へ戻る